Leap Therapeutics Inc (LPTX)

3.0800
-0.0700(-2.22%)
  • Volume:
    702,988
  • Bid/Ask:
    3.0800/3.0900
  • Day's Range:
    3.0400 - 3.1600

LPTX Overview

Prev. Close
3.15
Day's Range
3.04-3.16
Revenue
1.52M
Open
3.16
52 wk Range
1.33-4.17
EPS
-0.52
Volume
702,988
Market Cap
274.92M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
5,697,617
P/E Ratio
-
Beta
0.43
1-Year Change
43.84%
Shares Outstanding
87,277,113
Next Earnings Date
Nov 18, 2021
What is your sentiment on Leap Therapeutics Inc?
or
Vote to see community's results!

Leap Therapeutics Inc News

Leap Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellNeutralBuy
Technical IndicatorsSellStrong SellStrong SellStrong SellStrong Buy
SummarySellStrong SellStrong SellSellStrong Buy

Leap Therapeutics Inc Company Profile

Leap Therapeutics Inc Company Profile

Employees
30

Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company has two product pipelines: DKN-01 and TRX518. The Company's lead clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a cell secreted protein that research has found its role in embryonic development. DKN-01 is an affinity, neutralizing monoclonal antibody targeting DKK1. DKN-01 reduces free DKK1 levels and has demonstrated an anti-tumor effect in preclinical models. TRX518 is a humanized anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody designed for the immune system’s anti-tumor response as an immune checkpoint agonist.

Read More
  • hi
    0
    • https://twitter.com/gastriccancerfd/status/1227642373620015104?s=21
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.